We retrospectively examined the characteristics of 101 patients with GDM who underwent guideline-based glycemic control. A 75-g oral glucose tolerance test was conducted to diagnose GDM at gestational weeks 11-15 (ed-GDM subgroup) and 24-28 (md-GDM subgroup).
Infant birthweight was significantly lower in the ed-GDM subgroup (n = 25) than in the md-GDM subgroup (n = 76) (2688.3 ± 470.4 g vs. 3052.4 ± 383.1 g, p < 0.05), and the proportion of low-birthweight infants (<2500 g) was significantly higher in the ed-GDM subgroup than in the md-GDM subgroup (32.0% vs. 5.3%, p < 0.005). Fasting plasma glucose (FPG) levels during early treatment and before delivery were significantly lower in the ed-GDM subgroup than in the md-GDM subgroup (76.1 ± 10.4 mg/dL vs. 85.5 ± 9.6 mg/dL, p < 0.001; 80.5 ± 10.4 mg/dL vs. 90.4 ± 10.3 mg/dL, p < 0.0001).
Patients with ed-GDM showed significantly lower FPG levels during treatment compared to those with md-GDM, presumably indicating an association with the delivery of low-birthweight infants.
我们回顾性研究了101例GDM患者的特征,这些患者接受了基于指南的血糖控制。在孕周11-15(ed-GDM亚组)和24-28(md-GDM亚组)进行75g口服葡萄糖耐量试验以诊断GDM。
ed-GDM亚组(n=25)的婴儿出生体重明显低于md-GDM亚组(n=76)(2688.3±470.4gvs.3052.4±383.1g,p<0.05),ed-GDM亚组的低出生体重婴儿(<2500g)的比例显着高于md-GDM亚组(32.0%vs.5.3%,p<0.005)。ed-GDM亚组治疗早期和分娩前的空腹血糖(FPG)水平显着低于md-GDM亚组(76.1±10.4mg/dLvs.85.5±9.6mg/dL,p<0.001;80.5±10.4mg/dLvs.90.4±10.3mg/dL,p<0.0001)。
与md-GDM患者相比,ed-GDM患者在治疗期间的FPG水平显著降低,可能表明与低出生体重婴儿的分娩有关。